Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 2.70  0.05  1.82%   
About 53% of Lisata Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are impartial. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Lisata Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two months ago at finance.yahoo.com         
Xenetic Biosciences Third Quarter 2024 Earnings Misses Expectations
Yahoo News
over two months ago at seekingalpha.com         
Inhibrx Biosciences GAAP EPS of -2.84
seekingalpha News
over two months ago at finance.yahoo.com         
Willow Biosciences Third Quarter 2024 Earnings CA0.01 loss per share
Yahoo News
over two months ago at seekingalpha.com         
Cellectar Biosciences Q3 2024 Earnings Preview
seekingalpha News
over two months ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Increases Stake in Aptose Biosciences Inc
Gurufocus Stories at Macroaxis
over two months ago at finance.yahoo.com         
Akoya Biosciences Reports Third Quarter 2024 Financial Results
Yahoo News
over two months ago at finance.yahoo.com         
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
Yahoo News
over two months ago at gurufocus.com         
Senti Biosciences Inc Reports Q3 2024 Net Loss of 28.9 Million with No Revenue
Gurufocus Stories at Macroaxis
over two months ago at investing.com         
Akoya Biosciences earnings missed, revenue fell short of estimates
Investing News at Macroaxis
over two months ago at finance.yahoo.com         
Sparian Biosciences Announces Formation of its Science Advisory Board
Yahoo News
over two months ago at prnewswire.com         
Continuity Biosciences se lanza para permitir terapias innovadoras con nuevas tecnologas de administ...
prnewswire News
over two months ago at gurufocus.com         
Artelo Biosciences Stock Dips Amidst Financial Report
Gurufocus Stories at Macroaxis
over two months ago at gurufocus.com         
Cogent Biosciences Inc Reports Q3 2024 Net Loss Per Share of 0.64, Exceeding Analyst Estimates
Gurufocus Stories at Macroaxis
over two months ago at gurufocus.com         
Lisata Therapeutics Inc Reports Q3 2024 EPS of 0.59 and Net Loss of 4. ...
Gurufocus Stories at Macroaxis
over two months ago at seekingalpha.com         
Ensysce Biosciences GAAP EPS of 0.07 beats by 0.24
seekingalpha News
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Keymed Biosciences gibt die Zulassung von Stapokibart fr die Behandlung von chronischer Rhinosinusitis mit Nasenpolyposis bekannt
12/24/2024
2
Shareholders that lost money on Caribou Biosciences, Inc. ...
12/31/2024
3
Avidity Biosciences Announces Inducement Grants for New CTO
01/08/2025
4
Disposition of 2131 shares by James Nisco of Lisata Therapeutics at 3.8 subject to Rule 16b-3
01/13/2025
5
Ventyx Biosciences highlights 2025 pipeline strategy and provides clinical updates shares rise
01/14/2025
6
Colossal Biosciences takes de-extinction maintstream
01/15/2025
7
Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China
01/16/2025
8
Junshi Biosciences Announces Toripalimabs Approval in Australia
01/17/2025

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Money Managers
Screen money managers from public funds and ETFs managed around the world